Lenalidomide may be best maintenance for MM

Print Friendly, PDF & Email


Lenalidomide (Revlimid)
Photo courtesy of Celgene
Lenalidomide may be the best maintenance treatment option for patients with newly diagnosed multiple myeloma (MM), according to the authors of a systematic review and meta-analysis. Francesca M. Gay, MD, of the University of Torino in Italy, and her coauthors wrote that, despite the well-recognized importance of novel agent–based... [Read Article]
Print Friendly, PDF & Email

Study links communication, outcomes in cancer

Print Friendly, PDF & Email


Doctor consults with cancer
patient and her father
Photo by Rhoda Baer
Better communication between cancer patients and healthcare providers may provide tangible benefits, according to research published in JNCCN. Cancer survivors who reported greater satisfaction in communicating with healthcare providers had better general health and mental health, fewer doctor visits, and reduced healthcare spending,... [Read Article]
Print Friendly, PDF & Email

Tool identifies potential treatment for resistant MM

Print Friendly, PDF & Email


Micrograph showing
multiple myeloma
Researchers say they have developed a computational platform that can be used to identify optimal treatments for multiple myeloma (MM). Using this tool, the quadratic phenotypic optimization platform (QPOP), the researchers identified a 2-drug combination that proved effective against bortezomib-resistant MM in vitro. The combination—decitabine and mitomycin C—also decreased tumor... [Read Article]
Print Friendly, PDF & Email

Company stops development of drug for MM

Print Friendly, PDF & Email


Micrograph showing MM
MorphoSys AG has decided to stop developing MOR202 as a treatment for multiple myeloma (MM). However, MorphoSys said it will complete the ongoing phase 1/2a trial of MOR202, and I-Mab Biopharma will continue developing MOR202 as an MM therapy for the Greater China region. MOR202 is a human monoclonal HuCAL antibody directed... [Read Article]
Print Friendly, PDF & Email

CHMP backs generic lenalidomide

Print Friendly, PDF & Email


Lenalidomide (Revlimid)
Photo courtesy of Celgene
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval for Lenalidomide Accord as a treatment for multiple myeloma (MM). Lenalidomide Accord is a generic version of Revlimid, which has been authorized in the European Union since June 2007. The CHMP said studies have... [Read Article]
Print Friendly, PDF & Email

CHMP recommends expanded approval for daratumumab

Print Friendly, PDF & Email


Daratumumab (Darzalex)
Photo courtesy of Janssen
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended broadening the existing marketing authorization for daratumumab (Darzalex). The CHMP is recommending approval for daratumumab in combination with bortezomib, melphalan, and prednisone (VMP) for the treatment of adults with newly diagnosed multiple myeloma (MM) who... [Read Article]
Print Friendly, PDF & Email

CHMP backs 2 biosimilar pegfilgrastim products

Print Friendly, PDF & Email


Neulasta Onpro Kit
Photo from Amgen
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval for 2 pegfilgrastim biosimilar candidates—Udenyca and Pelgraz. Both products have been deemed highly similar to the reference product, Neulasta, a growth-colony-stimulating factor intended to reduce the duration of neutropenia and the incidence of febrile... [Read Article]
Print Friendly, PDF & Email

Team creates tool to assess frailty in MM

Print Friendly, PDF & Email


Doctor and patient
Photo courtesy of NIH
Researchers say they have developed a frailty index that can predict overall survival (OS) in patients newly diagnosed with multiple myeloma (MM). An increasing frailty index score was significantly associated with an increased risk of death in these patients, and frailty retained a significant association with OS even... [Read Article]
Print Friendly, PDF & Email

GPS receives fast track designation for MM

Print Friendly, PDF & Email


Bone marrow smear
showing multiple myeloma
The US Food and Drug Administration (FDA) has granted fast track designation to the cancer vaccine galinpepimut-S (GPS) for the treatment of multiple myeloma (MM). GPS consists of 4 modified peptide chains that induce an innate immune response (CD4+/CD8+ T cells) against the Wilms’ tumor 1 (WT1) antigen. GPS... [Read Article]
Print Friendly, PDF & Email

FDA approves biosimilar filgrastim

Print Friendly, PDF & Email


Vials of drug
Photo by Bill Branson
The US Food and Drug Administration (FDA) has approved the leukocyte growth factor Nivestym™ (filgrastim-aafi), a biosimilar to Neupogen (filgrastim). Nivestym is approved to treat patients with nonmyeloid malignancies who are receiving myelosuppressive chemotherapy or undergoing bone marrow transplant, acute myeloid leukemia patients receiving induction or consolidation chemotherapy,... [Read Article]
Print Friendly, PDF & Email